Radiopharmaceuticals for Persistent or Recurrent Uterine Cervix Cancer

被引：6

作者：

Kunos, Charles A. ^{[1
]}

Capala, Jacek ^{[2
]}

Kohn, Elise C. ^{[1
]}

Ivy, Susan Percy ^{[1
]}

机构：

[1] NCI, Canc Therapy Evaluat Program, Bethesda, MD 20892 USA

[2] NCI, Radiat Res Program, Bethesda, MD 20892 USA

来源：

FRONTIERS IN ONCOLOGY | 2019年 / 9卷

关键词：

radiopharmaceutical; targeted radioisotope therapy; uterine cervix cancer; cervical cancer; National Cancer Institute (NCI); 3-AMINOPYRIDINE-2-CARBOXALDEHYDE THIOSEMICARBAZONE 3-AP; RIBONUCLEOTIDE REDUCTASE INHIBITION; GYNECOLOGIC-ONCOLOGY-GROUP; PHASE-I TRIAL; RADIATION-THERAPY; EXTRAFASCIAL HYSTERECTOMY; PELVIC IRRADIATION; RANDOMIZED-TRIAL; DNA-DAMAGE; CELL-CYCLE;

D O I：

10.3389/fonc.2019.00560

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Uterine cervix cancers pose therapeutic challenges because of an overactive ribonucleotide reductase, which provides on-demand deoxyribonucleotides for DNA replication or for a DNA damage repair response. Ribonucleotide reductase overactivity bestows cancer cell resistance to the effects of radiotherapy and chemotherapy used to treat disease; but nevertheless, this same biologic overexpression provides opportune vulnerabilities relatively specific to uterine cervix cancers for new therapeutic strategies to take advantage. The discovery of human epidermal growth factor receptor 2 (ErbB2 or HER2) overexpression on metastatic uterine cervix cancer cells provides an opportunity for clinical trials of targeted radiopharmaceuticals in combination with DNA damage response modifying drugs. The National Cancer Institute's clinical trial infrastructure and its experimental therapeutics portfolio can now offer clinical trial evaluation ofmolecularly-targeted and tolerated radiopharmaceutical-drug combinations for women with persistent or recurrent metastatic uterine cervix cancer. This article discusses the current thinking of the National Cancer Institute in regard to attractive radiopharmaceutical strategies for this disease and others.

引用

页数：8

共 50 条

[1]

[Anonymous], 2019, Surveillance, Epidemiology, and End Results Program SEER Stat Databases

[2]

[Anonymous], 2019, Cancer Facts Figures for African Americans 2019-2021, P1

[3] FIGO staging for carcinoma of the vulva, cervix, and corpus uteri [J].

Belhadj, H. ;

Berek, J. ;

Bermudez, A. ;

Bhatla, N. ;

Cain, J. ;

Denny, L. ;

Fujiwara, K. ;

Hacker, N. ;

Avall-Lundqvist, E. ;

Mutch, D. ;

Odicino, F. ;

Pecorelli, S. ;

Prat, J. ;

Quinn, M. ;

Seoud, M. A-F. ;

Shrivastava, S. K. .

INTERNATIONAL JOURNAL OF GYNECOLOGY & OBSTETRICS, 2014, 125 (02) :97-98

[4] Cancer of the cervix uteri [J].

Bhatla, Neerja ;

Aoki, Daisuke ;

Sharma, Daya Nand ;

Sankaranarayanan, Rengaswamy .

INTERNATIONAL JOURNAL OF GYNECOLOGY & OBSTETRICS, 2018, 143 :22-36

[5] Integrated genomic and molecular characterization of cervical cancer [J].

Burk, Robert D. ;

Chen, Zigui ;

Saller, Charles ;

Tarvin, Katherine ;

Carvalho, Andre L. ;

Scapulatempo-Neto, Cristovam ;

Silveira, Henrique C. ;

Fregnani, Jose H. ;

Creighton, Chad J. ;

Anderson, Matthew L. ;

Castro, Patricia ;

Wang, Sophia S. ;

Yau, Christina ;

Benz, Christopher ;

Robertson, A. Gordon ;

Mungall, Karen ;

Lim, Lynette ;

Bowlby, Reanne ;

Sadeghi, Sara ;

Brooks, Denise ;

Sipahimalani, Payal ;

Mar, Richard ;

Ally, Adrian ;

Clarke, Amanda ;

Mungall, Andrew J. ;

Tam, Angela ;

Lee, Darlene ;

Chuah, Eric ;

Schein, Jacqueline E. ;

Tse, Kane ;

Kasaian, Katayoon ;

Ma, Yussanne ;

Marra, Marco A. ;

Mayo, Michael ;

Balasundaram, Miruna ;

Thiessen, Nina ;

Dhalla, Noreen ;

Carlsen, Rebecca ;

Moore, Richard A. ;

Holt, Robert A. ;

Jones, Steven J. M. ;

Wong, Tina ;

Pantazi, Angeliki ;

Parfenov, Michael ;

Kucherlapati, Raju ;

Hadjipanayis, Angela ;

Seidman, Jonathan ;

Kucherlapati, Melanie ;

Ren, Xiaojia ;

Xu, Andrew W. .

NATURE, 2017, 543 (7645) :378-+

[6]

Centers for Disease Control and Prevention (CDC), 2019, CERV CANC

[7] Controlled protein degradation regulates ribonucleotide reductase activity in proliferating mammalian cells during the normal cell cycle and in response to DNA damage and replication blocks [J].

Chabes, A ;

Thelander, L .

JOURNAL OF BIOLOGICAL CHEMISTRY, 2000, 275 (23) :17747-17753

[8] HER2 expression in cervical cancer as a potential therapeutic target -: art. no. 59 [J].

Chavez-Blanco, A ;

Perez-Sanchez, V ;

Gonzalez-Fierro, A ;

Vela-Chavez, T ;

Candelaria, M ;

Cetina, L ;

Vidal, S ;

Dueñas-Gonzalez, A .

BMC CANCER, 2004, 4 (1)

[9] A PROSPECTIVE SURGICAL PATHOLOGICAL-STUDY OF STAGE 1 SQUAMOUS CARCINOMA OF THE CERVIX - A GYNECOLOGIC ONCOLOGY GROUP-STUDY [J].

DELGADO, G ;

BUNDY, BN ;

FOWLER, WC ;

STEHMAN, FB ;

SEVIN, B ;

CREASMAN, WT ;

MAJOR, F ;

DISAIA, P ;

ZAINO, R .

GYNECOLOGIC ONCOLOGY, 1989, 35 (03) :314-320

[10] Pelvic irradiation with concurrent chemotherapy versus pelvic and para-aortic irradiation for high-risk cervical cancer: An update of radiation therapy oncology group trial (RTOG) 90-01 [J].

Eifel, PJ ;

Winter, K ;

Morris, M ;

Levenback, C ;

Grigsby, PW ;

Cooper, J ;

Rotman, M ;

Gershenson, D ;

Mutch, DG .

JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (05) :872-880

← 1 2 3 4 5 →